Omeros Corp. OMER, +41.15% shares surged 45% in extremely heavy morning trade Thursday on a new government spending bill that benefits its cataract surgery drug Omidria. Omidria's "pass-through" status with Medicare, which allows for a higher reimbursement rate, expired late last year, and the drug was expected to be bundled with other cataract surgery supplies, which might have forced Omeros to decrease the price "by up to 90 percent to remain competitive," said Height analyst Andrea Harris. Uncertainty around reimbursement affected Omidria's first-quarter sales, according to Omeros, and the company lobbied both legislatively and administratively to get pass-through status for a longer period of time. That seems to have worked: Lawmakers reinstated Omidria's pass-through status for two years starting October 1, Harris said. The spending bill, the text of which was recently made public, would fund the federal government through October, and Congress is expected to vote on it this week. Omeros shares have plummeted 16.4% over the last three months to $16.85, compared with a 0.6% decline in the S&P 500 SPX, -1.61%